WVE-006 is the first-ever RNA editing program to enter clinical development and is designed to restore production and circulation of functional, wild-type alpha-1 antitrypsin (AAT) protein and reduce ...

Presentations include new data showing WVE-006 improved markers of liver disease in mice; WVE-006 is a first-in-class RNA editing therapeutic for alpha-1 antitrypsin deficiency (AATD) which is ...

Achieved proof-of-mechanism for Wave’s RNA editing platform; restoring levels of wild-type (edited) M-AAT that are consistent with the heterozygous “MZ” genotype with low risk of AATD lung and liver ...

Wave Life Sciences specializes in oligonucleotide therapeutics, leveraging its RNA editing platform to develop treatments for a variety of genetic disorders. The company’s approach aims to provide ...

Wave Life Sciences Ltd. (NASDAQ: WVE) is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. The company is generating ...

Chemistry optimization yields a four-fold increase over PBS control in AAT protein restoration in vivo preclinically (or more than 15 micromolar) CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- ...

First proof-of-concept in vivo data for RNA editing using endogenous ADAR enzymes in alpha-1 antitrypsin deficiency ADAR editing resulted in therapeutically meaningful restoration of circulating ...

CRISPR/Cas9 genome editing has captured the attention of the popular media, the scientific community and the investment world: The promise of going into a cell and precisely making changes in its ...

Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company specializing in RNA editing oligonucleotides, is navigating a complex landscape of genetic medicine development. With an InvestingPro ...